# Study of ASN003 in Subjects With Advanced Solid Tumors

> **NCT02961283** · PHASE1 · TERMINATED · sponsor: **Asana BioSciences** · enrollment: 24 (actual)

## Conditions studied

- Neoplasms
- Melanoma
- Colorectal Neoplasm
- Carcinoma, Non-small Cell Lung

## Interventions

- **DRUG:** ASN003 ascending doses
- **DRUG:** ASN003 MTD

## Key facts

- **NCT ID:** NCT02961283
- **Lead sponsor:** Asana BioSciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2019-02
- **Final completion:** 2019-02
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** reformulation
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02961283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02961283, "Study of ASN003 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02961283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*